September 24, 2009
Bookmark and Share

WADA Emphasizes Importance of Cooperation with Pharmaceutical and Biotechnological Companies

In its efforts to anticipate doping trends and practices, WADA continues to closely cooperate with pharmaceutical and biotechnological companies, as well as medicine agencies and drug evaluation bodies.

On September 24, WADA’s Science Director, Dr. Olivier Rabin, participated in the “Bio(techno)logy of doping and the science of anti-doping” seminar organized by the Swiss Biotech Association in Lausanne.
 
On this occasion, he reiterated WADA’s stance on this growing cooperation. “This is an important avenue for the fight against doping in sport and a major strategy for the present and the future,” Dr. Rabin said. “Through win-win partnerships, the anti-doping community can better anticipate possible doping trends. At the same time, drug companies can help ensure that their work is directed at treating and healing patients suffering from illness and disease, not at providing healthy athletes with an unfair advantage over their competitors. WADA is very pleased with the level of cooperation it receives from a growing number of companies and organizations in this field.”